Hodgkin disease

An in-depth report on the causes, diagnosis, treatment, and prevention of Hodgkin disease.

I Would Like to Learn About:

Related Reports

References

American Cancer Society website. Key statistics for Hodgkin lymphoma. www.cancer.org/cancer/hodgkin-lymphoma/about/key-statistics.html. Updated January 8, 2019. Accessed August 13, 2019.

Ansell SM. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2015;90(11):1574-1583. PMID: 26541251 www.ncbi.nlm.nih.gov/pubmed/26541251.

Bartlett N, Triska G. Hodgkin lymphoma. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, eds. Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA: Elsevier; 2020:chap 102.

Bhakta N, Liu Q, Yeo F, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study. Lancet Oncol. 2016;17(9):1325-1334. PMID: 27470081 www.ncbi.nlm.nih.gov/pubmed/27470081.

Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(5):608-638. PMID: 28476741 www.ncbi.nlm.nih.gov/pubmed/28476741.

Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-2510. PMID: 23715580 www.ncbi.nlm.nih.gov/pubmed/23715580.

Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853-1862. PMID: 25796459 www.ncbi.nlm.nih.gov/pubmed/25796459.

Ng AK, van Leeuwen FE. Hodgkin lymphoma: late effects of treatment and guidelines for surveillance. Semin Hematol. 2016;53(3):209-215. PMID: 27496313 www.ncbi.nlm.nih.gov/pubmed/27496313.

PDQ Pediatric Treatment Editorial Board. Childhood Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-2019 May 29. PMID: 26389170 www.ncbi.nlm.nih.gov/pubmed/26389170.

PDQ Adult Treatment Editorial Board. Adult Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-2019 Jul 26. PMID: 26389473 www.ncbi.nlm.nih.gov/pubmed/26389473.

Smith K, Chiu A, Parikh R, Yahalom J, Younes A. Hodgkin lymphoma: clinical manifestations, staging, and therapy. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018:chap 75.

BACK TO TOP

Review Date: 9/4/2019  

Reviewed By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

ADAM Quality Logo

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complies with the HONcode standard for trustworthy health information: verify here.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2021 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.